Oncorus to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 26 2022 - 7:00AM
Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company
focused on driving innovation to transform outcomes for cancer
patients, today announced that President and Chief Executive
Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a
fireside chat at Chardan’s 6th Annual Genetic Medicines Conference
on Monday, October 3, 2022 at 2:00 p.m. ET in New York, NY.
A live webcast of the fireside chat can be accessed by visiting
the Investors & Media section of Oncorus’ website
at https://investors.oncorus.com/. A replay of the webcast
will be archived on Oncorus’ website for 90 days following the
event.
About Oncorus
At Oncorus, we are focused on driving innovation to deliver
next-generation viral immunotherapies to transform outcomes for
cancer patients. We are advancing a portfolio of intratumorally
(iTu) and intravenously (IV) administered viral immunotherapies for
multiple indications with significant unmet need based on our
Herpes Simplex Virus (HSV) and self-amplifying viral RNA
Immunotherapy Platforms.
Designed to deliver next-generation viral immunotherapy impact,
our HSV Platform improves upon key characteristics of this
therapeutic class to enhance systemic activity. Our lead HSV
program, ONCR-177, is designed to be directly administered into a
tumor, resulting in high local concentrations of the therapeutic
agent and its five encoded transgenes, as well as low systemic
exposure to the therapy, which could limit systemic toxicities. Our
pioneering self-amplifying vRNA Immunotherapy Platform, highlighted
by our product candidates ONCR-021 and ONCR-788, involves a highly
innovative, novel combination of RNA and oncolytic virus-based
modalities designed to realize the potential of RNA medicines for
cancer.
Please visit www.oncorus.com to learn more.
Investor Contact:Stern Investor
Relations Julie SeidelJulie.seidel@sternir.com
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Aug 2023 to Aug 2024